The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
 
Bruno Sangro
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; Roche/Genentech; Sirtex Medical; TERUMO
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; Lilly; Roche; Sirtex Medical
Research Funding - Bristol-Myers Squibb (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Sirtex Medical
 
Peter R Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Guerbet; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Exelixis/Ipsen (Inst); Genentech/Roche; Gilead Sciences; Kinnate Biopharma; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Chaiyut Charoentum
Research Funding - AstraZeneca; Novartis; Roche/Genentech
 
Enrico N De Toni
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Research Funding - AstraZeneca; Bayer; Bristol-Myer Squibb; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Roche
 
Yuriy Ostapenko
No Relationships to Disclose
 
Jeong Heo
No Relationships to Disclose
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche
 
Arndt Vogel
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daichi-Sankyo; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Daichi-Sankyo; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Roche
 
Michelle Marcovitz
Employment - AstraZeneca
 
Jayne Abraham
Employment - IQVIA
Consulting or Advisory Role - AstraZeneca
 
Nikunj Patel
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Alejandra Negro
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); SOBI (I); Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris